a developer of technology related to biomarkers, has added life-sciences veteran executive Edward Erickson to its board of directors.

“Ed brings extensive experience in commercializing diagnostic products to our team at a time when we are moving our diagnostic offerings in diabetes and prostate cancer into development,” said Metabolon Chief Executive Officer John Ryals.

Metabolon has developed patented technology around metabolomics (an approach to identifying biomarkers) that it says will "dramatically impact drug discovery and development processes." Metabolomics is the study of small molecules, such as glucose and cholesterol that are produced by cellular metabolism. The metabolome is the catalog of those molecules in a specific organism.

The technology can be used to identify safer compounds for drug development and thus shorten time to market. Metabolon also says biomarkers can indicate an early presence of a disease.

Erickson has served as CEO or a board member with more than 12 life-science firms, four of which went public during his tenure. He received an MBA from the Harvard Business School.